Susan Haigney

Industry experts discuss how FDA’s response to COVID-19 and related pandemic-related guidance documents may impact the biologics industry long term.

Understanding an FDA corrective and preventive actions request is step one in developing a robust plan to address CGMP deficiencies.

The agency’s focus appears to be on generic drugs for the upcoming year.

Outsourcing increases as the industry balances development and manufacturing of both COVID-19 treatments and non-pandemic-related medicines.

USP is preparing for 2021 while also supporting the development of vaccines and treatments for COVID-19.

The European Pharmacopoeia is preparing for 2021 while also supporting the industry to develop vaccines and treatments for COVID-19.

Industry experts discuss challenges and best practices for scaling up manufacturing under a short deadline.

The COVID-19 pandemic has highlighted the challenges and complications of sourcing, tracking, and testing materials for pharmaceuticals. Pharmaceutical Technology spoke with Joe DiMartino, Luminata solution manager at ACD/Labs about the impact COVID-19 is having on the pharmaceutical supply chain and how companies can prepare for these challenges.

The COVID-19 pandemic has raised several questions about the safety of the pharmaceutical materials supply chain. Is onshoring the answer?

Pharmaceutical Technology spoke with Matthew Woodcock, director of LLamasoft, a supply chain analytics company that assists companies in their decision-making and supply chain challenges, about the impact the COVID-19 pandemic has had on the pharmaceutical supply chain.

Hiring the right quality consultant can provide expertise and save costs.

Industry experts discuss the challenges and regulations of setting up a CGMP-compliant stability testing program.

The complex nature of biologics adds additional CQAs that must be determined to ensure the safe development of biologics